Celltrion Group is moving forward with business plans to diversify into the development of its own new drugs, showcasing early data on several antibody-drug conjugate (ADC) candidates.
The South Korea firm, already a major global player in biosimilars, has also decided to set up a wholly-owned contract development manufacturing organization (CDMO) subsidiary to pursue growth opportunities in the sector as part of its efforts to become
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?